



## PRESS RELEASE

### **Forepont Capital Partners raises \$130 million for its fund dedicated to French, European and American Biotech and Medtech companies**

Paris, April 12, 2021 - The Franco-American investment fund Forepont Capital Partners specialized in the healthcare sector, has raised nearly \$130 million for its second fund and has already invested in six companies in France and the United States. The VC is targeting a \$200 million closing by summer 2021 to continue investing in the most promising biotech and medtech companies, mainly in France, Europe and the US.

Launched in New York in 2014 by Eric Attias, Forepont Capital Partners built strong relationships with a group of key stakeholders in the healthcare sector. It benefits from a first-class network, mainly due to its Neurogen Research Foundation, founded in 2013, which includes doctors, major universities, world-renowned hospitals and executives from the largest pharmaceutical groups.

### **Supporting the financing of biotech and medtech companies and becoming one of the leading venture capital funds in France in the healthcare sector.**

Forepont Capital Partners has raised \$130 million from private investors in the United States and Europe (France, United Kingdom, Switzerland). This second fund comes after a first fund launched in 2015, which was ranked top decile and included the San Diego-based decacorn company Samumed and the Belfast-based gene therapy biotech SiSaf.

*"Forepont Capital Partners was founded with the aim of supporting innovative initiatives, creating impact and performance. We are delighted to welcome new investors who share our values"* Eric Attias Managing Partner.

Forepont Capital Partners is a venture capital fund dedicated to life sciences and medical technology, driven by the expertise and track record of its founders:

- Eric Attias (successful entrepreneur),
- Julien Tizot (Institutional investor & startup manager),
- Dr Ismail Kola (Scientific Director of major pharmaceutical groups),
- Dr Larry Rubin (Expert and pioneer in artificial intelligence).

Thanks to this 360° approach, Forepont Capital Partners supports startups in Europe and the United States with scientific, technological, operational and financial capacities.

*"In addition to our investment, we bring scientific, technological and operational knowledge to transform high-potential startups into true international champions."* Julien Tizot General Partner.

Forepont Capital Partners also relies on exemplary governance. Its board of directors is composed of pharmaceutical industry executives (Johnson & Johnson, UCB, Merck, Allergan) and influential entrepreneurs in Europe and the United States. Its scientific committee is made up of leading



experts in their fields. Its ethics committee, led by Jacques Attali, brings together the views of international experts.

## **Supporting the growth of start-ups and creating opportunities between Europe and the US**

Forepont Capital Partners 2 is expected to invest in around twenty start-ups, mainly in series A and B, providing strong financial and operational support. The ambition is to provide strategic, organizational and go-to-market insights to the management team and create connections with a first-class ecosystem to increase their performance and strengthen their market positioning.

*"We are putting our international science and AI network to work, in addition to the recognized and complementary expertise of our team to enhance European excellence."* according to Dr Ismail Kola, General Partner

Since 2020, Forepont Capital Partners has been supporting the strong development of French biotech BioSpeedia. It helped founders to make strategic decisions by relocating BioSpeedia's industrial capacities of diagnosis tests to France. It helped the biotech partnering with the Saint-Etienne University Hospital for scientific research, and with Delpharm and BPIFrance to increase local production capacities. In just a few months, the spin-off from the Institut Pasteur has become one of the leading biotech in the field of rapid tests for COVID-19 in France and Europe, serving both for governments and private companies.

Forepont Capital Partners is also looking to prepare the international expansion of its start-ups and to strengthen their network in Europe and the United States. The fund is expected to announce the sale of one of its US start-ups to a French group, marking a breakthrough in technology acquisitions.

*"Europe has some of the strongest growth potential in the healthcare sector and an exceptional talent pool. As our recent investments confirm, our model of acceleration through the transfer of global experience and complementary expertise has enabled us to rapidly amplify the value creation of our European champions. It is a virtuous and sustainable model where start-ups, our performance and our medical and social impact win."* concludes Eric Attias.

### **About Forepont Capital Partners**

Forepont Capital Partners is an impact investment fund specializing in the healthcare sector based in Paris and New York. The fund manages nearly \$130 million in assets between Europe and the United States. Its particularity is based on active participation, including taking an operational role in companies to structure them, enable them to develop their activity and guide them towards profitability. Convinced of the importance of investing in the future and the common good, Forepont Capital Partners donates 10% of its revenues to the Neurogen Research Foundation.